Legend Biotech Corporation (LEGN)

Legend Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	901.9	286.7	1,278	786.03	688.94
Short-Term Investments	46.7	835.9	30.34	54.02	193.46
Trading Asset Securities	-	-	0.66	185.6	-
Cash & Short-Term Investments	948.6	1,123	1,309	1,026	882.4
Cash Growth	-15.50%	-14.22%	27.60%	16.23%	74.49%
Accounts Receivable	13.1	6.4	101.43	0.28	50.5
Other Receivables	237.2	118.7	55.63	44.24	8.04
Receivables	250.3	125.1	157.06	44.52	58.55
Inventory	32	23.9	19.43	10.35	1.75
Prepaid Expenses	14.6	12.3	12.23	17.33	5.72
Other Current Assets	1.6	-	0.36	1.27	1.44
Total Current Assets	1,247	1,284	1,498	1,099	949.85
Property, Plant & Equipment	401.5	201.2	189.23	160.76	140.79
Long-Term Investments	-	-	4.36	-	4.71
Other Intangible Assets	-	-	4.06	3.41	4.68
Long-Term Accounts Receivable	-	-	-	0.4	-
Other Long-Term Assets	85.1	185.1	153.16	67.28	19.44
Total Assets	1,734	1,670	1,849	1,331	1,119
Accounts Payable	83	38.6	30.66	32.89	7.04
Accrued Expenses	123	64.5	61.58	152.73	104.38
Current Portion of Long-Term Debt	319.1	-	-	-	-
Current Portion of Leases	7.4	4.8	3.18	3.56	0.91
Current Income Taxes Payable	19.2	20.7	7.2	9.77	9.49
Current Unearned Revenue	11.3	47.4	53.08	0.45	0.3
Other Current Liabilities	73.4	101.7	60.73	98.38	107.08
Total Current Liabilities	636.4	277.7	216.42	297.79	229.2
Long-Term Debt	-	301.2	281.33	260.93	120.46
Long-Term Leases	87.2	44.6	44.17	20.04	1.59
Long-Term Unearned Revenue	-	6.1	55.27	7.66	1.87
Other Long-Term Liabilities	8	-	0.06	0.23	0.4
Total Liabilities	731.6	629.6	597.24	586.65	353.52
Common Stock	0.1	0.1	0.04	0.03	0.03
Additional Paid-In Capital	2,750	2,696	2,637	1,657	1,261
Retained Earnings	-1,959	-1,662	-1,485	-966.46	-520.11
Comprehensive Income & Other	210.2	6.2	98.93	53.72	24.57
Shareholders' Equity	1,002	1,041	1,251	744.31	765.94
Total Liabilities & Equity	1,734	1,670	1,849	1,331	1,119
Total Debt	413.7	350.6	328.67	284.53	122.97
Net Cash (Debt)	534.9	772	980.05	741.12	759.43
Net Cash Growth	-30.71%	-21.23%	32.24%	-2.41%	51.28%
Net Cash Per Share	2.90	4.22	5.57	4.66	5.39
Filing Date Shares Outstanding	184.94	183.65	181.91	165.07	154.23
Total Common Shares Outstanding	184.94	183.65	181.91	165.07	154.23
Working Capital	610.7	1,006	1,281	801.33	720.65
Book Value Per Share	5.42	5.67	6.88	4.51	4.97
Tangible Book Value	1,002	1,041	1,247	740.9	761.26
Tangible Book Value Per Share	5.42	5.67	6.86	4.49	4.94
Land	2.9	2.9	2.89	2.89	2.89
Buildings	66	65.5	65.54	45.08	16.01
Machinery	57.5	45	45.48	46.26	38.27
Construction In Progress	14.2	4.4	3.04	14.18	41.37
Leasehold Improvements	22.6	21.3	23.12	21.97	20.91

Updated Mar 10, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q